|
|
1#
Big Middle
Small posted on Apr 11, 2008 20:43 Only show author
Expert Opinion on Drug Discovery, 2008 April, Volume 3, Number 4
Free Content:Editorial
2 R9 E2 \$ ~4 u' F2 I5 `- j) i
) R) v6 g# M5 \- h1 l- Q8 h+ d Academic institutions and industry: bridging the gap
+ e1 ?4 r, i& h/ l$ f3 c% lKarl G Hofbauer
1 P2 ?7 Q4 D# p. W; h; ?9 uExpert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 369-373.
* F" ^' H, X5 m! A% H; |; p1 Z4 a5 L: V
Reviews + O' a- S5 k0 D& [+ x
* {6 ~; T! {3 Q8 L& K) r
A perspective on more effective GPCR-targeted drug discovery efforts1 V, c* h8 K3 W% f
Annette Gilchrist* ?2 _: z/ S, b. I, ~' r6 x
Expert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 375-389.
% t# B" u( }5 G; V8 O( @0 q6 b5 I
# j- Z+ n6 P- K: | A structural biology view of target drugability( x6 H$ i+ l% w
Ursula Egner, Roman C Hillig
4 D3 l7 M" [# V$ eExpert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 391-401.
X2 B0 p' Y- T0 jSummary | Full Text | PDF (922 KB) | PDF Plus (986 KB) 7 p; m" V! m0 W1 H! K {
) O% A( I2 i0 t! N: a
GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity: K& _8 B# L8 f/ U* Y0 j1 d
Matthew CT Fyfe, James G McCormack, Hilary A Overton, Martin J Procter, Christine Reynet
( {5 _: d2 v+ m; J* C/ `Expert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 403-413.9 Y; @9 K* M$ ~2 T8 J1 J8 G8 p
* ~3 P8 k+ D9 R5 ?' u5 V1 @7 B" J
Development of influenza virosome-based synthetic malaria vaccines( P* L# j; _1 m. }- o3 C
Claudia A Daubenberger, Gerd Pluschke, Rinaldo Zurbriggen, Nicole Westerfeld1 m& ?# ~5 X- U4 X3 ^% ]* u; Q
Expert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 415-423.
' E: n% b" d* r; z, e0 x. f( `- R5 Y U4 U
Peptidomics in drug research0 G9 i" F# B# J" O' \5 Y: U
E Clynen, G Baggerman, SJ Husson, B Landuyt, L Schoofs
" }' ~4 p: j- V/ oExpert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 425-440.0 c7 @# ]$ y& P5 a8 Z
( k/ J4 |1 ~" V0 @ Antibody-based cancer therapy
9 A# x7 S. ?" o1 R; I$ s) [Constantin N Baxevanis
3 n! `( F$ r& X( Z* t1 |: Z1 W& YExpert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 441-452." J2 j% U% m# y; P3 v& Y$ T
/ m5 L9 S) [! p4 w" iCase History ) X# Z3 ~: d. Z( S3 @3 c1 V
; U; g! e, l) c- l6 Z% p( g
Stiripentol – characteristic of a new antiepileptic drug+ Y. _# ~' o8 K9 U$ W0 n: ?
Stanislaw J Czuczwar, Michal K Trojnar, Aleksandra Gergont, Slawomir Kroczka, Marek Kacinski/ n3 a; O- {* R3 E8 E; y& M0 T1 H8 X
Expert Opinion on Drug Discovery, April 2008, Vol. 3, No. 4, Pages 453-460.' L) t/ `6 q4 s2 v" |, g/ [
the hidden contents only visible for repliers
|
